ArticleClinical, cosmetic and investigational dermatology2026
A Preliminary Study of Polycaprolactone Filler After Hyaluronidase for Facial Overfilled Syndrome.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyaluronidase effectively degrades hyaluronic acid (HA) fillers in facial overfilled syndrome (FOS). However, the subsequent volume reduction may create soft tissue hollowing and contour irregularities. Objective: To evaluate the aesthetic and structural changes following polycaprolactone (PCL) filler injection after hyaluronidase treatment in patients with FOS. Methods: This single-arm, retrospective study enrolled patients with FOS who underwent hyaluronidase treatment followed by a PCL injection. Outcomes included Global Aesthetic Improvement Scale (GAIS), upper cheek fullness, temporal hollowing, 3D midfacial volume, and ultrasound-measured soft tissue-to-bone distance. Assessments were performed at baseline, after hyaluronidase, and at 3 and 6 months post-PCL treatment. Results: 12 patients were enrolled. At 6 months after PCL injection, improvements were observed in GAIS (P < 0.001) and upper cheek fullness (P = 0.016). Using the pre-hyaluronidase state as baseline, the 3D midfacial filler volume decreased by 2.48 mL after hyaluronidase injection (P < 0.001), by 4.88 mL at 3 months after PCL treatment (P < 0.001), and by 5.14 mL at 6 months after PCL treatment (P < 0.001). Conversely, the ultrasound-assessed distance from soft tissue to bone surface was 1.21 mm greater than baseline after hyaluronidase treatment (P < 0.001), and 2.09 mm and 3.23 mm lower than baseline at 3 and 6 months after PCL injection, respectively (both P < 0.001). No adverse events were reported after hyaluronidase and PCL treatment. Conclusion: In this preliminary study, aesthetic improvement and changes in soft tissue parameters were observed after PCL injection following hyaluronidase treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.